C12N 2760/18722
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18722 (New viral proteins or individual genes, new structural or functional aspects of) appears on 77 US grants and 50 published applications in this corpus.
Search patents in C12N- Granted patents
- 77
- Published applications
- 50
- Assignees
- 47
- Inventors
- 119
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 1 | 0 |
| 1998 | 11 | 0 |
| 1999 | 5 | 0 |
| 2000 | 9 | 0 |
| 2001 | 7 | 0 |
| 2002 | 1 | 1 |
| 2003 | 5 | 5 |
| 2004 | 3 | 6 |
| 2005 | 2 | 0 |
| 2006 | 2 | 1 |
| 2007 | 1 | 5 |
| 2008 | 4 | 6 |
| 2009 | 0 | 1 |
| 2010 | 3 | 2 |
| 2011 | 2 | 4 |
| 2012 | 0 | 0 |
| 2013 | 1 | 3 |
| 2014 | 1 | 0 |
| 2015 | 2 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 1 |
| 2019 | 1 | 1 |
| 2020 | 1 | 1 |
| 2021 | 0 | 0 |
| 2022 | 1 | 3 |
| 2023 | 1 | 1 |
| 2024 | 1 | 3 |
| 2025 | 2 | 3 |
| 2026 | 3 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/PIV3 F protein and uses thereof2 Jun 2026US 12,643,925 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Paramyxovirus virus-like particles as protein delivery vehicles14 Apr 2026US 12,600,956 B2The Penn State Research Foundation
- Transient expression of biologic materials17 Mar 2026US 12,576,041 B1
- F-genotype mumps virus attenuated strain and construction method therefor and application thereof2 Dec 2025US 12,486,497 B2Beijing Cell-Fusion Biotechnology Co., Ltd.
- Paramyxovirus virus-like particles as protein delivery vehicles1 Apr 2025US 12,264,338 B2The Penn State Research Foundation
- Anticancer agent, pharmaceutical composition for cancer treatment, kit, and activator20 Aug 2026US 2026/0240929 A1BioComo Incorporation
- Piv5-based covid-19 vaccine12 Mar 2026US 2026/0069674 A9University of Georgia Research Foundation, Inc.
- Piv5-based covid-19 vaccine16 Oct 2025US 2025/0319176 A1University of Georgia Research Foundation, Inc.
- Paramyxovirus virus-like particles as protein delivery vehicles10 Jul 2025US 2025/0223572 A1The Penn State Research Foundation
- Viral vectors3 Jul 2025US 2025/0213674 A1City, University of London
Most cited
By later US patents
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Genetically engineered vaccine strain89US 5,364,773 AVirogenetics Corporation · 1994
- Pox virus containing DNA encoding a cytokine and/or a tumor associated antigen89US 6,265,189 B1Virogenetics Corporation · 2001
- Modified recombinant vaccinia virus and expression vectors thereof65US 5,762,938 AVirogenetics Corporation · 1998